Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Excaliard Pharmaceuticals

Request full access

Biotechnology company developing antisense drugs for the local treatment of scarring and other fibrotic diseases

Carlsbad, United StatesFounded 2006Biotech & Life Sciences

About Excaliard Pharmaceuticals

Excaliard Pharmaceuticals, Inc. operated as a biopharmaceutical company with a specific focus on developing treatments for skin fibrosis, commonly known as scarring. Founded in 2006 by Nicholas Dean, the company established itself to address the market for skin scarring and other fibrotic disorders. One of the company's co-founders, J. Gordon Foulkes, also served as CEO and was a managing director at RiverVest Venture Partners, one of the venture capital firms that provided initial funding.

The company's business model centered on the development and eventual commercialization of novel drugs. Excaliard operated on a virtual model with a small number of full-time employees, outsourcing a significant portion of its operations. This lean structure was supported by a single Series A funding round of $15.5 million in 2007 from investors including Alta Partners, ProQuest Investments, and RiverVest Venture Partners. A key part of its strategy involved a partnership with Isis Pharmaceuticals (now Ionis Pharmaceuticals), from which it licensed the core antisense technology for its lead product candidate.

Excaliard’s primary asset was EXC 001, an antisense oligonucleotide drug candidate designed to treat skin scarring. The product works by inhibiting the expression of Connective Tissue Growth Factor (CTGF), a protein that is over-expressed in damaged tissue and contributes to the formation of disfiguring scars. The potential market for such a treatment is substantial, covering scarring from millions of surgical procedures performed annually. After demonstrating positive results in Phase II clinical trials for reducing scar severity, Excaliard became an attractive acquisition target. In late 2011, Pfizer Inc. announced its acquisition of Excaliard, a deal completed in December of that year for an undisclosed sum involving an upfront payment and future milestone-based payments. The acquisition allowed Pfizer to integrate EXC 001 into its R&D pipeline to address the unmet need for an FDA-approved treatment for excessive skin scarring.

Source: Dealroom company data

At a glance

Status
Acquired
Employees
2
Open positions
None listed
Dealroom signal
24.3/100
Industry
Health
Sub-industry
BioTechnology
Sector
Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
Business model
Manufacturing
Client focus
B2B

Funding history

2 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
ACQUISITION✓Exit Nov 2011 $0 — Pfizer —
SERIES A✓Equity / VC Nov 2007 $16M $62M Alta Partners · RiverVest Venture Partners · ProQuest Investments —
Showing the latest 2 of 2 recorded eventsBook a demo for the full funding history →

Growth signals

Excaliard Pharmaceuticals website traffic

Latest recorded traffic for Excaliard Pharmaceuticals is 380 monthly website visits, up 660% over the last three months. Excaliard Pharmaceuticals's team grew 0% over the past year.

Latest monthly visits380 3-month web change+660% 1-year team growth0%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

CompanyHeadquartersStatusEmployeesTotal fundingValuation
Lyopor3D collagen scaffold for 3D cell culture, suitable for testing the behavior of a wide range of cells in their natural 3D environment Brno, Czechia Operational — $132K $528K
Evergreen TheragnosticsContract development and manufacturing of therapeutic radiopharmaceuticals Jersey City, United States Acquired
A.D.A.M.A.D.A.M. is a biotech company that targets artificial bones and tissues market, using it proprietary 3D printing technology. A.D.A.M. focuses on 3D printing of different tissues (initially bones) made of patented organic materials, which can be scala Stamford, United States Operational
AC BioscienceA clinical stage biotech company focused on novel approaches to provide more effective treatments for solid tumor cancer patients Ecublens, Switzerland Operational
Sapreme TechnologieDevelops new technologies within the field of macromolecule therapeutics such as antibody-drug conjugates and oligonucleotide-based therapeutics Driebergen-Rijsenburg, Netherlands Operational
CerecinHealthcare company that develops a novel evidence-based therapeutics, and products that aim to help people Denver, United States Operational
Skyhawk TherapeuticsA drug discovery and development company focused on revolutionizing disease treatment with small molecules that correct RNA expression Waltham, United States Operational
Onkos SurgicalSurgical oncology company that develops implants and instruments for musculoskeletal tumor patients Parsippany-Troy Hills, United States Operational
Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Excaliard Pharmaceuticals in the Carlsbad ecosystem

Live from Dealroom

The Excaliard Pharmaceuticals office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

4 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A3 investors entered at this stage

  • Alta Partners
  • RiverVest Venture Partners
  • ProQuest Investments

Other known investors1 additional known investor

  • Pfizer
Team profiled 3 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators Hidden — book a demo quality score
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
🇺🇸 United States · Carlsbad HQ
Book a demo for the full country breakdown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Excaliard Pharmaceuticals on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Excaliard Pharmaceuticals’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.